Hacettepe Üniversitesi Onkoloji Hastanesi Medikal Onkoloji Ve Radyasyon Onkolojisi Bölümlerine 2008-2017 Tarihleri Arasında Başvuran Düşük Dereceli Glial Tümör Tanılı Hastaların Klinopatolojik Özellikleri Ve Tedavi Sonuçları

Abstract

Clinopathologic Features and Treatment Results of Patients with Low Grade Glial Tumor Apply to Hacettepe University Oncology Hospital, Department of Medical Oncology and Radiation Oncology, between 2008-2017, Thesis in Internal Medicine, Ankara, 2018. Low-grade gliomas (LGG) are rare tumors that are diagnosed at young age, have potential for malignant transformation, and have overall survival (OS) close to 10 years. In recent years, molecular and molecular changes become more important in diagnosis and treatment. Retrospective studies are generally available in the literature. In this study, it was aimed to examine the clinopathological features of LGG patients and to see their effects on survival. For this aim, 189 LGG patients admitted to Medical Oncology and Radiation Oncology departments between 2008-2017 were included in the study. Median follow-up was 5.5 years (minimum 6 months, maximum 26.3 years). Median duration of OS was 10.5 years (95% CI 8.8-12.3), 5-year OS rate was 83%, and 10-year OS rate was 55%. In univariate survival analysis, OS of oligoastrocytoma was found to be shorter than OS of oligodendroglioma (p: 0.002), while patients with undetermined grade subtype tumors were shorter than those of GS patients with grade I and II tumors (p: 0.01). According to the multivariate analysis by Cox-regression analysis, OS of oligoastrocytoma subtype was lower than the oligodendroglioma subtype (HR: 2.8, 95% GA: 1.1-6.8, p: 0.026) and OS of undetermined grade subtype tumors was lower than grade I and II tumors (HR: 23.9 %95 GA3.3-169.8). Median duration of progression-free survival (PFS) was 3.4 years (95% CI 2.8-4.0). In univariate survival analysis, it was seen that PFS of the patients with undetermined grade subtype tumors was shorter than that of patients with grade I and II tumors (p: 0.001). Presence of IDH1 mutation (p: 0.001) and absence of TP53 mutation (p: 0.004) were associated longer PFS. According to multivariate survival analysis, the absence of IDH1 mutation shortened PFS (HR: 29.2, 95% CI: 3.2-264.6, p: 0.003). In the recurrent patients, median duration of post-recurrence survival was 4.8 years (95% CI 3.2-6.4).